Predictive dosimetric parameters for gastrointestinal toxicity with hypofractioned radiotherapy in p

来源 :2016年北京市肿瘤放疗年会 | 被引量 : 0次 | 上传用户:fanke26
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  To better guide the development and optimization of radiotherapy planning, to reduce the incidence of radiation reactions, and to improve the quality of life of the patients with pancreatic cancer using radiotherapy, we conducted this study to explore the dosimetric parameters that predict the risk of gastrointestinal (GI) toxicity with hypofractioned radiotherapy for pancreatic cancer.Between January 2014 and January 2015, the medical records of 68 patients with pancreatic cancer who underwent helical tomotherapy at the Air Force General Hospital were analyzed.The doses delivered to the planning target volume, clinical target volume, and gross tumor volume-internal gross tumor volume of the primary pancreatic lesions were 50, 60, and 70-80 Gy in 15-20 fractions, respectively.GI toxicity was scored according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events.The stomach and duodenum were contoured separately to determine the dose-volume histogram parameters.Univariate and multivariate analyses were adopted to identify clinical and physical risk factors associated with GI toxicity.The median follow-up was 9 months (range: 4-16 months).Eighteen patients had grade Ⅱ acute GI toxicity, one patient had grade Ⅲ acute GI toxicity, 17 patients had grade Ⅱ late GI toxicity, and one patient had grade Ⅲ late GI toxicity.On univariate analysis, the volume, the average dose Dmean, the maximum dose to 1, 3, 5, and 10 cm3 of the stomach and duodenum (D1, D3, D5, and D10),and the relative volumes receiving 5-40 Gy (V5-V40), and the absolute volumes receiving 5-45 Gy (aV5-aV45) of the duodenum were significantly associated with grade Ⅱ or higher GI toxicity (P<0.05).On multivariate analysis, aV45 of the duodenum was an independent predictor for grade Ⅱ or higher GI toxicity (P=0.031).The receiver operating characteristic analysis also showed that an aV45 of 0.5 cm3 was the optimal threshold to predict GI toxicity for the entire cohort.Our findings indicate that many dosimetric parameters of the duodenum correlate with grade Ⅱ or higher GI toxicity.To reduce GI toxicity, the absolute volume of the irradiated duodenum should be reduced.
其他文献
Background:Platelet to lymphocyte ratio (PLR) is a parameter reflecting inflammatory responses in patients with cancer.Several studies have investigated the prognostic value of PLR in patients with co
会议
会议
目的:对具有术后复发高危因素的上尿路输尿管癌(UTUC)患者行术后辅助放疗是上尿路输尿管癌综合治疗的一部分.本研究分析上尿路输尿管癌患者术后局部复发模式,为术后辅助放疗临床靶区(CTV)勾画提供指导.方法:分析2010-2015年在北京大学第一医院泌尿外科行肾输尿管癌全长切除术,术后局部复发的UTUC患者首次出现的膀肤或区域淋巴结复发情况。患者膀肤复发及具体复发部位依据影像记录和我院膀肤镜检查结果
目的:转移性前列腺癌在指南里首选化疗、内分泌治疗等全身治疗,参照其他实体瘤如肺癌、乳腺癌,寡转移病历选择根治性治疗手段也能获得很好的疗效.放射治疗和手术治疗均为前列腺癌的根治手段.有关手术根治寡转移前列腺癌的研究较多,但同时对原发灶和转移灶进行根治性放疗的研究较少.本研究回顾性分析我单位采用根治性放疗治疗寡转移前列腺癌的患者的近期疗效和生活质量.方法:回顾性分析北京大学第一医院放疗科2011年至2
会议
目的:肺癌放疗后复发是目前的治疗难点,往往治疗手段有限、预后不佳,由于多为姑息治疗,需要平衡治疗方案的疗效、安全性及患者的生活质量.本次研究意在分析放射性I-125粒子植入治疗放疗后复发肺癌的初步疗效及安全性.方法:纳入自2015.01至2016.10于本科接受放射性I-125粒子植入治疗的肺癌放疗后复发患者的数据,分析粒子植入治疗的疗效及安全性.粒子植入流程按科内常规进行,包据术前计划设计、术中
目的:探讨复方红豆杉胶囊联合体部伽玛刀(γ-ray Stereotactic Body Radiation Therapy,γ-SBRT)对局部晚期胰腺癌的治疗效果及安全性.方法:2013年8月~2014年9月收治48例局部晚期胰腺癌患者,随机分为两组,研究组25例:采用体部伽玛刀治疗,50%~60%等剂量曲线覆盖95%以上临床靶体积(Clinical targetvolume,CTV),3.0~
目的:对比替吉奥或吉西他滨联合射波刀治疗老年局部晚期或转移性胰腺癌的疗效和安全性.方法:2013年8月至2015年8月,我中心收治的60例胰腺癌患者按化疗方案不同随机分为G、S两组,每组30例.所有患者接受针对胰腺及周围转移性腹膜后淋巴结病灶的射波刀治疗,采用25-40Gy/5f,5f/周的高分次剂量治疗模式.G组同步化疗:吉西他滨,1g,VD,qd,d1、8.S组同步化疗:替吉奥胶囊,40mg,
目的:通过分析肝癌碘油栓塞后瘤体的血管结构特点与碘油沉积的关系以及碘油在瘤体内沉积的特点与疗效的关系,总结出栓塞后碘油分布及密集程度对肝癌预后有指导意义,对进一步放射治疗提供有力的依据.方法:选取肝癌行肝动脉栓塞化疗(TACE)术后患者,一般介入治疗1-2次后行放射治疗,并于TACK治疗后1-2周开始进行。按照国际辐射单位和测量委员会(ICRU)50号文件规定标准,由放疗科和CT室医师在TPS工作